India, Nov. 10 -- Glenmark Specialty S.A., a wholly-owned subsidiary of Glenmark Pharmaceuticals Ltd, has received approval from China's National Medical Products Administration (NMPA) for its RYALTRIS® Compound Nasal Spray (GSP 301 NS), marking a major milestone in its respiratory portfolio.
The approval covers the treatment of moderate to severe seasonal allergic rhinitis (AR) in adults and children aged six and above, and perennial AR in adults and children aged twelve and above.
RYALTRIS®, Glenmark's first globally commercialized branded specialty product, combines olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid) in a fixed-dose nasal spray. The drug is already approved in the US, EU, UK, Austr...